Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

92.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 92.94
Bid (Size) 80.00 (2)
Ask (Size) 97.00 (5)
Prev. Close 92.94
Today's Range 92.94 - 92.94
52wk Range 76.02 - 117.77
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace

Performance

YTD
-7.62%
-7.62%
1 Month
+10.67%
+10.67%
3 Month
+2.29%
+2.29%
6 Month
-0.41%
-0.41%
1 Year
-12.54%
-12.54%

More News

Read More
3 Promising Biotech Stocks Flying Under the Radar
Via InvestorPlace
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
Via Investor's Business Daily
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Outlook For Biomarin Pharmaceutical
Via Benzinga
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2023
Via The Motley Fool
15 Analysts Have This to Say About Biomarin Pharmaceutical
Via Benzinga
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Earnings Outlook For Biomarin Pharmaceutical
Via Benzinga
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Biomarin's Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand
Via Benzinga
Earnings Scheduled For July 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.